1. Academic Validation
  2. Enabling non-viral DNA delivery using lipid nanoparticles co-loaded with endogenous anti-inflammatory lipids

Enabling non-viral DNA delivery using lipid nanoparticles co-loaded with endogenous anti-inflammatory lipids

  • bioRxiv. 2024 Jun 12:2024.06.11.598533. doi: 10.1101/2024.06.11.598533.
Manthan N Patel 1 2 Sachchidanand Tiwari 2 3 Yufei Wang 2 Sarah O'Neill 1 Jichuan Wu 2 Serena Omo-Lamai 2 4 Carolann Espy 1 2 Liam S Chase 2 4 Aparajeeta Majumdar 2 Evan Hoffman 2 Anit Shah 2 András Sárközy 3 Jeremy Katzen 2 Norbert Pardi 3 Jacob S Brenner 1 2
Affiliations

Affiliations

  • 1 Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • 2 Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine University of Pennsylvania Philadelphia, PA, USA.
  • 3 Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • 4 Department of Bioengineering, School of Engineering & Applied Science, University of Pennsylvania, Philadelphia, PA, USA.
Abstract

Lipid nanoparticles (LNPs) have transformed genetic medicine, recently shown by their use in COVID-19 mRNA vaccines. While loading LNPs with mRNA has many uses, loading DNA would provide additional advantages such as long-term expression and availability of promoter sequences. However, here we show that plasmid DNA (pDNA) delivery via LNPs (pDNA-LNPs) induces acute inflammation in naïve mice which we find is primarily driven by the cGAS-STING pathway. Inspired by DNA viruses that inhibit this pathway for replication, we co-loaded endogenous lipids that inhibit STING into pDNA-LNPs. Specifically, loading nitro-oleic acid (NOA) into pDNA-LNPs (NOA-pDNA-LNPs) ameliorates serious inflammatory responses in vivo enabling prolonged transgene expression (at least 1 month). Additionally, we demonstrate the ability to iteratively optimize NOA-pDNA-LNPs' expression by performing a small LNP formulation screen, driving up expression 50-fold in vitro. Thus, NOA-pDNA-LNPs, and pDNA-LNPs co-loaded with other bioactive molecules, will provide a major new tool in the genetic medicine toolbox, leveraging the power of DNA's long-term and promoter-controlled expression.

Figures
Products